These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 19543848)
1. Is the current therapeutic armamentarium in diabetes enough to control the epidemic and its consequences? What are the current shortcomings? Giugliano D; Standl E; Vilsbøll T; Betteridge J; Bonadonna R; Campbell IW; Schernthaner GH; Staels B; Trichopoulou A; Farinaro E Acta Diabetol; 2009 Sep; 46(3):173-81. PubMed ID: 19543848 [TBL] [Abstract][Full Text] [Related]
2. New treatments in type 2 diabetes: a focus on the incretin-based therapies. Barnett AH Clin Endocrinol (Oxf); 2009 Mar; 70(3):343-53. PubMed ID: 18771570 [TBL] [Abstract][Full Text] [Related]
3. Fate of the beta-cell in the pathophysiology of type 2 diabetes. Campbell RK J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360 [TBL] [Abstract][Full Text] [Related]
4. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. Pratley RE J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254 [No Abstract] [Full Text] [Related]
5. Impact of glucagon-like peptide-1 on endothelial function. Sjöholm A Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():19-25. PubMed ID: 19878258 [TBL] [Abstract][Full Text] [Related]
9. Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. Ranganath LR J Clin Pathol; 2008 Apr; 61(4):401-9. PubMed ID: 18375745 [TBL] [Abstract][Full Text] [Related]
10. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Inzucchi SE; McGuire DK Circulation; 2008 Jan; 117(4):574-84. PubMed ID: 18227398 [TBL] [Abstract][Full Text] [Related]
11. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Chilton R; Wyatt J; Nandish S; Oliveros R; Lujan M Am J Med; 2011 Jan; 124(1 Suppl):S35-53. PubMed ID: 21194579 [TBL] [Abstract][Full Text] [Related]
12. Incretin based therapies for type 2 diabetes mellitus. Ghosh S; Collier A; Elhadd T; Malik I J Indian Med Assoc; 2008 Jun; 106(6):373-4, 383, 388. PubMed ID: 18839649 [TBL] [Abstract][Full Text] [Related]
13. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. Mannucci E; Rotella CM Nutr Metab Cardiovasc Dis; 2008 Nov; 18(9):639-45. PubMed ID: 18849155 [TBL] [Abstract][Full Text] [Related]
14. Incretins: the novel therapy of type 2 diabetes. Thongtang N; Sriwijitkamol A J Med Assoc Thai; 2008 Jun; 91(6):943-54. PubMed ID: 18697398 [TBL] [Abstract][Full Text] [Related]
15. Improving the pharmacological regimen for patients with diabetes mellitus. Marso SP Rev Cardiovasc Med; 2004; 5(3):139-47. PubMed ID: 15346097 [TBL] [Abstract][Full Text] [Related]
16. Glucokinase activators in diabetes management. Coghlan M; Leighton B Expert Opin Investig Drugs; 2008 Feb; 17(2):145-67. PubMed ID: 18230050 [TBL] [Abstract][Full Text] [Related]
17. Current trends and new approaches in the management of diabetes mellitus. Kao PC; Wu TJ; Ho LL; Li XJ Ann Clin Lab Sci; 2000 Oct; 30(4):339-45. PubMed ID: 11045757 [TBL] [Abstract][Full Text] [Related]
18. Basic approach to managing hyperglycemia for the nonendocrinologist. Deeg MA Am J Cardiol; 2005 Aug; 96(4A):37E-40E. PubMed ID: 16098842 [TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapy in chronic kidney disease. Pinelli NR; Moore CL; Tomasello S Adv Chronic Kidney Dis; 2010 Sep; 17(5):439-49. PubMed ID: 20727514 [TBL] [Abstract][Full Text] [Related]